ArticleFrontiers in oncology2024
Development of a new VMAT QA framework for Mobius3D using control-point specific EPID images.
Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Validation of SRS MapCHECK for CyberKnife patient-specific quality assurance: challenges with small cone sizes.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study presents novel quality assurance (QA) approach for volumetric modulated arc therapy (VMAT) that leverages frame-by-frame electronic portal imaging device (EPID) images integrated into Mobius3D for accurate three-dimensional dose calculations. Methods: Sequential EPID images for VMAT plans were acquired every 0.4-second by iView system and processed through iterative deconvolution to mitigate blurring from photon scattering. Deconvolved images were binarized to define multi-leaf collimator (MLC) positions. Pre-acquired box fluences determined optimal threshold for binarization and adjusted for detector shift depending on gantry and collimator angles. Sequential EPID images were re-scaled using pixel scaling factor (PSF) and converted to monitor unit (MU) proportional values. Generated EPID-based log file, including control-point specific MLC and monitor units (MU) information, were analyzed in Mobius3D for Gamma passing rate (GPR) of VMAT plans from 18 patients. Plan complexity indices were calculated and correlated with GPR. Results: Clinically appropriate threshold was defined to be 20000 that can extract accurate MLC data from the deconvolved binarized EPID images. Positional deviations due to gantry and collimator rotations were observed to be up to 4.5 pixels. Recalibrated EPID pixel values showed linearity with MU regardless of changes in dose rate. Consequently, average GPR for 18 patients evaluated using Mobius3D reached 95.2% ± 3.7%%, based on 3% dose difference and 3mm distance-to-agreement criterion. It was found that two plan complexity indices showed statistically significant correlation with GPR. Conclusion: This study successfully implemented novel measurement-based VMAT QA framework based on control-point specific EPID, based upon accurate MLC and MU data at each frame.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.